PR Newswire January 24, 2023
The Kroger Co.

Announcement comes with the collaboration with biopharmaceutical industry to introduce colorectal cancer clinical trial

CINCINNATI, Jan. 24, 2023 /PRNewswire/ — Kroger Health, the healthcare division of The Kroger Co. (NYSE: KR), today announced the establishment of its clinical trial site network in conjunction with pharmaceutical industry sponsors, contract research organizations, and health systems. The announcement comes with Kroger’s first trial in active recruitment for colorectal cancer gut and immune health observation.

In collaboration with Persephone Biosciences, Kroger Health is actively recruiting for the ARGONAUT clinical study (NCT04638751) to identify microbiome-based biomarkers indicative of colorectal cancer. Beginning in the Toledo, Ohio area, select Kroger pharmacies and its affiliate, The Little Clinic LLC, locations will enroll its initial cohort of 55 people...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Clinical Trials, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Retailer, Survey / Study, Trends
Related Articles:
Researchers explore 9 more diseases GLP-1s could treat
Eli Lilly Shows Obesity Drug Zepbound Can Treat Sleep Apnea Too
Opinion: Even with new law, clinical trials lack data on older adults
Eli Lilly's tirzepatide scores again, this time in 2 sleep apnea trials
Eli Lilly’s weight loss drug Zepbound shows promise as a sleep apnea treatment in late-stage trials

Share This Article